RxDoctor Payments Data

Amy Sidorski

Nurse Practitioner · Aurora, CONPI 1114191368

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $64,300 of the $96,531 with a category attached, or 66.6%. 18 manufacturers reported payments, led by Genentech USA, Inc. at 52.8% of the total. Reporting peaked in 2023 at $33,337 and has fallen 64.3% since, to $11,908 in 2025. Among nurse practitioner clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$96,531in general payments, 2019–2025

Across 216 payments — averaging $446.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$51K
  • AbbVie$38K
  • GSK$2K
  • Sanofi$2K
  • Johnson & Johnson$1K
  • Janssen Scientific Affairs, LLC$1K
  • plus $1K from 12 others

What the payments were for

  • Consulting fees$10,91811%
  • Speaking & faculty fees$64,30067%
  • Travel & lodging$15,80216%
  • Food & beverage$5,4246%
  • Education$870%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$96,531 in reported general payments places this provider in the 95th percentile of 1,384 nurse practitioner providers in Colorado.

See all nurse practitioner providers in Colorado

Medicare billing

Part B allowed, 2024
$139,851
Medicare patients
273
Services billed
3,222

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CalquenceAcalabrutinib Maleate25$386,143
BrukinsaZanubrutinib20$297,430
JakafiRuxolitinib Phosphate23$281,283
EliquisApixaban74$53,415
XareltoRivaroxaban38$42,988
Xtampza ErOxycodone Myristate20$7,921
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen32$1,189
Gabapentin59$1,025
Potassium Chloride36$971
Acyclovir64$672
Pregabalin34$514
Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine20$499
Dexamethasone28$455
Pantoprazole Sodium19$389
Hydroxyurea17$313

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$1,424$42,98838 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,384 nurse practitioner providers in Colorado.

Other nurse practitioner in Aurora

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →